Compare XBP & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBP | NSRX |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.3M | 38.9M |
| IPO Year | 2021 | 2024 |
| Metric | XBP | NSRX |
|---|---|---|
| Price | $3.20 | $3.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $19.67 |
| AVG Volume (30 Days) | ★ 26.0K | 14.2K |
| Earning Date | 05-15-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 183.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $872,690,000.00 | N/A |
| Revenue This Year | $2.59 | N/A |
| Revenue Next Year | $5.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $1.98 |
| 52 Week High | $8.55 | $9.50 |
| Indicator | XBP | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.82 | 50.48 |
| Support Level | $2.10 | $2.97 |
| Resistance Level | $3.87 | $3.60 |
| Average True Range (ATR) | 0.28 | 0.27 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 42.48 | 68.73 |
XBP Global Holdings Inc is a multinational technology and services company that drives intelligent workflows for organizations. Through its proprietary platforms, agentic AI-driven automation, and domain expertise across industries and the public and private sectors, the firm enables its clients to entrust their digital transformations and workflows. The segments of the company are Applied Workflow Automation and Technology. The Applied Workflow Automation segment generates maximum revenue and provides services powered by intelligent, AI-enabled workflows that generate outcomes for client's systems, while the Technology segment focuses on the sale of recurring and perpetual software licenses, software maintenance and professional services, as well as hardware solutions and maintenance.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.